schliessen

Filtern

 

Bibliotheken

The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study

Rectal cancer, defined as a cancerous lesion of the colon distal to the rectosigmoid junction, is the fourth most common cancer cause of death globally. There were 474 patients with rectal cancer who underwent surgery between October 2007 and May 2013 enrolled in our center. Patients were respective... Full description

Journal Title: Tumor biology 2015-10-08, Vol.37 (3), p.3441-3449
Main Author: Li, Qing
Other Authors: Peng, Yu , Wang, Lin-Ang , Wei, Xi , Li, Meng-Xia , Qing, Yi , Xia, Wei , Cheng, Ming , Zi, Dan , Li, Chun-Xue , Wang, Dong
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Dordrecht: Springer Netherlands
ID: ISSN: 1010-4283
Link: https://www.ncbi.nlm.nih.gov/pubmed/26449827
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1784750933
title: The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study
format: Article
creator:
  • Li, Qing
  • Peng, Yu
  • Wang, Lin-Ang
  • Wei, Xi
  • Li, Meng-Xia
  • Qing, Yi
  • Xia, Wei
  • Cheng, Ming
  • Zi, Dan
  • Li, Chun-Xue
  • Wang, Dong
subjects:
  • Aged
  • Analysis
  • Biomedical and Life Sciences
  • Biomedicine
  • Cancer
  • Cancer Research
  • Cancer therapies
  • Chemoradiotherapy
  • Chemotherapy
  • Colorectal cancer
  • Disease-Free Survival
  • Female
  • Health aspects
  • Humans
  • Male
  • Medical prognosis
  • Medical research
  • Medicine, Experimental
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Original Article
  • Prognosis
  • Rectal Neoplasms - mortality
  • Rectal Neoplasms - pathology
  • Rectal Neoplasms - therapy
  • Retrospective Studies
ispartof: Tumor biology, 2015-10-08, Vol.37 (3), p.3441-3449
description: Rectal cancer, defined as a cancerous lesion of the colon distal to the rectosigmoid junction, is the fourth most common cancer cause of death globally. There were 474 patients with rectal cancer who underwent surgery between October 2007 and May 2013 enrolled in our center. Patients were respectively categorized by neoadjuvant therapy. This study aimed to explore the predictive factors that affected the Progression-free survival and overall survival of the patients with rectal cancer. Clinical characteristics of patients were compared with the groups and potential prognostic factors were analyzed by SPSS 19.0. In our study, neoadjuvant therapy increased the anus-retained rate (64.4 vs 53.4 % P  = 0.016) and remission rate in the treatment group, compared to the non-treatment group (62.6 vs 34.8 %; P  = 0.000). The neoadjuvant concurrent chemoradiotherapy, more operative duration, anus retained and micturition damaged are positive prognostic factors of PFS to patients. Poor differentiation, the tumor of ulcer, invasive, and pT4 stage, contributed the poor factors for PFS of patients ( P  
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1010-4283
fulltext: fulltext
issn:
  • 1010-4283
  • 1423-0380
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.3492963
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1784750933
sourceformatXML
sourcesystemPC
galeidA450606308
sourcerecordidA450606308
originalsourceidFETCH-LOGICAL-c354t-c96049d460eeeadedd98317c382734c5dd046bb03f378d37d34e8aa394889b5f3
addsrcrecordideNp1kU9v1DAQxSMEoqXwAbggS1y4pNgZJ3G4VRX_pEpcytny2pNdrxI72E7RfntmlYIQEvLBo5nfGz37VdVrwa8F5_37LKDp-5qLtpaihZo_qS6FbKgAxZ9SzQWvZaPgonqR85ETOAzd8-qi6aQcVNNfVvH-gMyHcVoxWGRxZAGjccf1wYTCygGTWU5sjOlcsyXFfYjZZ5KwxRSPoWT205cDS2iLmZg1yfoQZ_OBGeqVFPNCE_-ALJfVnV5Wz0YzZXz1eF9V3z99vL_9Ut99-_z19uauttDKUtuh43JwsuOIaBw6NygQvQUyDdK2znHZ7XYcRuiVg96BRGUMDFKpYdeOcFW92_aS5R8r5qJnny1Ok6H3rVmLXsm-5QMAoW__QY9xTYHcnSkYQEIniLreqL2ZUNOPxZKMpeNw9jYGHD31b2TLO94BVyQQm8DSH-SEo16Sn006acH1OT69xacpFX2OT3PSvHm0su5mdH8Uv_MioNmATKOwx_SX1_9u_QU2GaW2
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1783934361
display
typearticle
titleThe influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study
sourceAlma/SFX Local Collection
creatorLi, Qing ; Peng, Yu ; Wang, Lin-Ang ; Wei, Xi ; Li, Meng-Xia ; Qing, Yi ; Xia, Wei ; Cheng, Ming ; Zi, Dan ; Li, Chun-Xue ; Wang, Dong
creatorcontribLi, Qing ; Peng, Yu ; Wang, Lin-Ang ; Wei, Xi ; Li, Meng-Xia ; Qing, Yi ; Xia, Wei ; Cheng, Ming ; Zi, Dan ; Li, Chun-Xue ; Wang, Dong
descriptionRectal cancer, defined as a cancerous lesion of the colon distal to the rectosigmoid junction, is the fourth most common cancer cause of death globally. There were 474 patients with rectal cancer who underwent surgery between October 2007 and May 2013 enrolled in our center. Patients were respectively categorized by neoadjuvant therapy. This study aimed to explore the predictive factors that affected the Progression-free survival and overall survival of the patients with rectal cancer. Clinical characteristics of patients were compared with the groups and potential prognostic factors were analyzed by SPSS 19.0. In our study, neoadjuvant therapy increased the anus-retained rate (64.4 vs 53.4 % P  = 0.016) and remission rate in the treatment group, compared to the non-treatment group (62.6 vs 34.8 %; P  = 0.000). The neoadjuvant concurrent chemoradiotherapy, more operative duration, anus retained and micturition damaged are positive prognostic factors of PFS to patients. Poor differentiation, the tumor of ulcer, invasive, and pT4 stage, contributed the poor factors for PFS of patients ( P  < 0.05). Additionally, the patients with neoadjuvant concurrent chemoradiotherapy and adjuvant chemotherapy underwent the better prognosis of OS. Adjuvant chemotherapy cannot increase PFS of the patients who accepted neoadjuvant therapy after surgery get pCR, but can improve OS. The anus-retained and neoadjuvant radiotherapy, duration of surgery in rectal cancer have the positive correlation. Micturition damaged and neoadjuvant radiotherapy were positively correlated as well. In conclusion, adjuvant chemotherapy does not improve the PFS of patients with pCR to neoadjuvant therapy, but is good for OS. Further prospective and large population-based clinical studies are needed to establish clinical guidelines for the use of neoadjuvant therapy and adjuvant chemotherapy in patients with rectal cancer.
identifier
0ISSN: 1010-4283
1EISSN: 1423-0380
2DOI: 10.1007/s13277-015-4153-0
3PMID: 26449827
languageeng
publisherDordrecht: Springer Netherlands
subjectAged ; Analysis ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; Cancer therapies ; Chemoradiotherapy ; Chemotherapy ; Colorectal cancer ; Disease-Free Survival ; Female ; Health aspects ; Humans ; Male ; Medical prognosis ; Medical research ; Medicine, Experimental ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Original Article ; Prognosis ; Rectal Neoplasms - mortality ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; Retrospective Studies
ispartofTumor biology, 2015-10-08, Vol.37 (3), p.3441-3449
rights
0International Society of Oncology and BioMarkers (ISOBM) 2015
1COPYRIGHT 2016 Springer
2International Society of Oncology and BioMarkers (ISOBM) 2016
lds50peer_reviewed
citesFETCH-LOGICAL-c354t-c96049d460eeeadedd98317c382734c5dd046bb03f378d37d34e8aa394889b5f3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26449827$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Li, Qing
1Peng, Yu
2Wang, Lin-Ang
3Wei, Xi
4Li, Meng-Xia
5Qing, Yi
6Xia, Wei
7Cheng, Ming
8Zi, Dan
9Li, Chun-Xue
10Wang, Dong
title
0The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study
1Tumor biology
addtitle
0Tumor Biol
1Tumour Biol
descriptionRectal cancer, defined as a cancerous lesion of the colon distal to the rectosigmoid junction, is the fourth most common cancer cause of death globally. There were 474 patients with rectal cancer who underwent surgery between October 2007 and May 2013 enrolled in our center. Patients were respectively categorized by neoadjuvant therapy. This study aimed to explore the predictive factors that affected the Progression-free survival and overall survival of the patients with rectal cancer. Clinical characteristics of patients were compared with the groups and potential prognostic factors were analyzed by SPSS 19.0. In our study, neoadjuvant therapy increased the anus-retained rate (64.4 vs 53.4 % P  = 0.016) and remission rate in the treatment group, compared to the non-treatment group (62.6 vs 34.8 %; P  = 0.000). The neoadjuvant concurrent chemoradiotherapy, more operative duration, anus retained and micturition damaged are positive prognostic factors of PFS to patients. Poor differentiation, the tumor of ulcer, invasive, and pT4 stage, contributed the poor factors for PFS of patients ( P  < 0.05). Additionally, the patients with neoadjuvant concurrent chemoradiotherapy and adjuvant chemotherapy underwent the better prognosis of OS. Adjuvant chemotherapy cannot increase PFS of the patients who accepted neoadjuvant therapy after surgery get pCR, but can improve OS. The anus-retained and neoadjuvant radiotherapy, duration of surgery in rectal cancer have the positive correlation. Micturition damaged and neoadjuvant radiotherapy were positively correlated as well. In conclusion, adjuvant chemotherapy does not improve the PFS of patients with pCR to neoadjuvant therapy, but is good for OS. Further prospective and large population-based clinical studies are needed to establish clinical guidelines for the use of neoadjuvant therapy and adjuvant chemotherapy in patients with rectal cancer.
subject
0Aged
1Analysis
2Biomedical and Life Sciences
3Biomedicine
4Cancer
5Cancer Research
6Cancer therapies
7Chemoradiotherapy
8Chemotherapy
9Colorectal cancer
10Disease-Free Survival
11Female
12Health aspects
13Humans
14Male
15Medical prognosis
16Medical research
17Medicine, Experimental
18Middle Aged
19Neoadjuvant Therapy
20Neoplasm Staging
21Original Article
22Prognosis
23Rectal Neoplasms - mortality
24Rectal Neoplasms - pathology
25Rectal Neoplasms - therapy
26Retrospective Studies
issn
01010-4283
11423-0380
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNp1kU9v1DAQxSMEoqXwAbggS1y4pNgZJ3G4VRX_pEpcytny2pNdrxI72E7RfntmlYIQEvLBo5nfGz37VdVrwa8F5_37LKDp-5qLtpaihZo_qS6FbKgAxZ9SzQWvZaPgonqR85ETOAzd8-qi6aQcVNNfVvH-gMyHcVoxWGRxZAGjccf1wYTCygGTWU5sjOlcsyXFfYjZZ5KwxRSPoWT205cDS2iLmZg1yfoQZ_OBGeqVFPNCE_-ALJfVnV5Wz0YzZXz1eF9V3z99vL_9Ut99-_z19uauttDKUtuh43JwsuOIaBw6NygQvQUyDdK2znHZ7XYcRuiVg96BRGUMDFKpYdeOcFW92_aS5R8r5qJnny1Ok6H3rVmLXsm-5QMAoW__QY9xTYHcnSkYQEIniLreqL2ZUNOPxZKMpeNw9jYGHD31b2TLO94BVyQQm8DSH-SEo16Sn006acH1OT69xacpFX2OT3PSvHm0su5mdH8Uv_MioNmATKOwx_SX1_9u_QU2GaW2
startdate20151008
enddate20151008
creator
0Li, Qing
1Peng, Yu
2Wang, Lin-Ang
3Wei, Xi
4Li, Meng-Xia
5Qing, Yi
6Xia, Wei
7Cheng, Ming
8Zi, Dan
9Li, Chun-Xue
10Wang, Dong
general
0Springer Netherlands
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
97T5
107TO
11H94
12K9.
137X8
sort
creationdate20151008
titleThe influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study
authorLi, Qing ; Peng, Yu ; Wang, Lin-Ang ; Wei, Xi ; Li, Meng-Xia ; Qing, Yi ; Xia, Wei ; Cheng, Ming ; Zi, Dan ; Li, Chun-Xue ; Wang, Dong
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c354t-c96049d460eeeadedd98317c382734c5dd046bb03f378d37d34e8aa394889b5f3
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Aged
1Analysis
2Biomedical and Life Sciences
3Biomedicine
4Cancer
5Cancer Research
6Cancer therapies
7Chemoradiotherapy
8Chemotherapy
9Colorectal cancer
10Disease-Free Survival
11Female
12Health aspects
13Humans
14Male
15Medical prognosis
16Medical research
17Medicine, Experimental
18Middle Aged
19Neoadjuvant Therapy
20Neoplasm Staging
21Original Article
22Prognosis
23Rectal Neoplasms - mortality
24Rectal Neoplasms - pathology
25Rectal Neoplasms - therapy
26Retrospective Studies
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Li, Qing
1Peng, Yu
2Wang, Lin-Ang
3Wei, Xi
4Li, Meng-Xia
5Qing, Yi
6Xia, Wei
7Cheng, Ming
8Zi, Dan
9Li, Chun-Xue
10Wang, Dong
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8Immunology Abstracts
9Oncogenes and Growth Factors Abstracts
10AIDS and Cancer Research Abstracts
11ProQuest Health & Medical Complete (Alumni)
12MEDLINE - Academic
jtitleTumor biology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Li, Qing
1Peng, Yu
2Wang, Lin-Ang
3Wei, Xi
4Li, Meng-Xia
5Qing, Yi
6Xia, Wei
7Cheng, Ming
8Zi, Dan
9Li, Chun-Xue
10Wang, Dong
formatjournal
genrearticle
ristypeJOUR
atitleThe influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study
jtitleTumor biology
stitleTumor Biol
addtitleTumour Biol
date2015-10-08
risdate2015
volume37
issue3
spage3441
epage3449
pages3441-3449
issn1010-4283
eissn1423-0380
abstractRectal cancer, defined as a cancerous lesion of the colon distal to the rectosigmoid junction, is the fourth most common cancer cause of death globally. There were 474 patients with rectal cancer who underwent surgery between October 2007 and May 2013 enrolled in our center. Patients were respectively categorized by neoadjuvant therapy. This study aimed to explore the predictive factors that affected the Progression-free survival and overall survival of the patients with rectal cancer. Clinical characteristics of patients were compared with the groups and potential prognostic factors were analyzed by SPSS 19.0. In our study, neoadjuvant therapy increased the anus-retained rate (64.4 vs 53.4 % P  = 0.016) and remission rate in the treatment group, compared to the non-treatment group (62.6 vs 34.8 %; P  = 0.000). The neoadjuvant concurrent chemoradiotherapy, more operative duration, anus retained and micturition damaged are positive prognostic factors of PFS to patients. Poor differentiation, the tumor of ulcer, invasive, and pT4 stage, contributed the poor factors for PFS of patients ( P  < 0.05). Additionally, the patients with neoadjuvant concurrent chemoradiotherapy and adjuvant chemotherapy underwent the better prognosis of OS. Adjuvant chemotherapy cannot increase PFS of the patients who accepted neoadjuvant therapy after surgery get pCR, but can improve OS. The anus-retained and neoadjuvant radiotherapy, duration of surgery in rectal cancer have the positive correlation. Micturition damaged and neoadjuvant radiotherapy were positively correlated as well. In conclusion, adjuvant chemotherapy does not improve the PFS of patients with pCR to neoadjuvant therapy, but is good for OS. Further prospective and large population-based clinical studies are needed to establish clinical guidelines for the use of neoadjuvant therapy and adjuvant chemotherapy in patients with rectal cancer.
copDordrecht
pubSpringer Netherlands
pmid26449827
doi10.1007/s13277-015-4153-0